Tier 4 — mechanistic

Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting

Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R
Frontiers in aging 2026 7; 1652582

Bibliography

PubMed
PMID 41704678
PubMed Central
PMC12907335
DOI
10.3389/fragi.2026.1652582
Funding
Restore Hyper Wellness funded the study; Niagen Biosciences donated NR.
Competing interests
The authors were employed by Restore Hyperwellness.

Study snapshot

DesignRetrospective real-world tolerability comparison
ModelHuman participants
Sample14 clients: 6 NAD+ IV and 8 NR IV
InterventionNR IV or NAD+ IV, 500 mg/day
Duration4 consecutive infusion days; 30-day follow-up
EndpointsInfusion symptoms; infusion time; safety markers

What the study showed, in plain terms

The retrospective comparison reported shorter infusions and fewer acute symptoms with NR IV than with NAD+ IV.

Key findings

The retrospective comparison reported shorter infusions and fewer acute symptoms with NR IV than with NAD+ IV.

What this study can and cannot tell us

Nonrandomized commercial-clinic records and exploratory laboratory outcomes; results do not establish oral NR effects, injection efficacy or long-term infusion safety.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology